Skip to main content

PeptideAuthority

Home
Peptides A–Z
Comparisons
Stacks
Science
Safety & Legal
Blog
Glossary

Loading...

PeptideAuthority

The UK & EU's definitive peptide education and research platform. Evidence-based information for informed decision-making.

Peptide Categories

Peptides A–Z
Healing & Recovery
Fat Loss & Metabolic
Longevity & Anti-Ageing
Cognitive & Neurological
Hormonal & Endocrine

Research Guides

Tendon Injuries
Fat Loss
Muscle Growth
Anti-Ageing
Cognitive Enhancement
All Guides

Tools

All Tools
Evidence Explorer
Athlete Risk Checker
Peptide Claim Checker
Clinic Claims Checker
Claim Interaction Explorer
GLP-1 Access Explainer
GLP-1 Eligibility Checker
Reconstitution Maths Explainer
Lab Interpreter
Citations

Community

Community Forum
Challenges
Join Free
Sign In

Resources

Start Here
About Us
Blog
Stacks
Science & Mechanisms
Comparisons
Glossary
FAQ
Safety Centre
UK Law
GLP-1 Centre
Stack claim reviews
Safety & Legal
Clinics
Contact Us

Trust, Policies & Standards

All policies & standards
Editorial Standards
Editorial Board
Corrections Policy
Conflict of Interest
Affiliate Disclosure
No dosing, no sourcing
How to use this site safely
Medical Disclaimer

Trusted Sources

PubMed
ClinicalTrials.gov
NHS
European Medicines Agency

Medical Disclaimer: The information provided on this website is for educational and informational purposes only. It is not intended as medical advice, diagnosis, or treatment. Peptides discussed are not approved medicines in the UK or EU. Always consult a qualified healthcare professional before making any decisions regarding your health. This content reflects the UK and EU research context.

© 2026 Peptide Authority. All rights reserved.

Privacy Policy Terms of Use Cookie Policy Medical Disclaimer Editorial Standards

Home
Stacks
Claim reviews

Fact-checked by the Peptide Authority Editorial Board · Last reviewed: 16 May 2026

Stack claim reviews

Peptide stack claim reviews

Popular peptide combinations get a lot of online marketing. These pages compare what is claimed against what the evidence supports, plus the UK regulatory and athlete anti-doping picture. We do not publish dosing, cycle, injection, or stacking instructions — these are claim-reviews, not protocols.

Educational content only

This page is educational information about peptide research and UK regulation. It is not medical advice, not diagnosis, not treatment, not a prescription, and not dosing or injection guidance. It is not a substitute for advice from a registered pharmacist or doctor. See our full medical disclaimer.

Unlicensed compound — please read

Not approved as a UK medicine, unless specifically licensed for a stated indication.
Educational information only — not medical advice, not dosing guidance, not a prescription.
Speak to a qualified healthcare professional before considering any unlicensed compound.
Do not buy prescription-only medicines without a prescription. See how to check a UK pharmacy.
Do not use social-media sellers. See social-media seller warnings.
Report suspected fake or harmful medicines to MHRA via the Yellow Card scheme.

BPC-157 + TB-500 — claim review

The internet's most heavily-marketed 'healing stack'. We look at what is claimed, why it is popular, what the human evidence base actually contains, and the UK regulatory and athlete anti-doping picture.

CJC-1295 + Ipamorelin — claim review

Growth-hormone-releasing peptide combination commonly marketed for 'anti-ageing' and 'body composition'. Unlicensed in the UK, prohibited in sport, and a clear example of clinic claim drift.

Semaglutide + AOD-9604 — claim review

A licensed UK medicine paired with an unlicensed compound — a combination some clinics market without acknowledging the regulatory asymmetry. The risks of mixing a POM with a grey-market peptide.

Melanotan II + PT-141 — claim review

Two melanocortin receptor agonists marketed for tanning and sexual function. MHRA's stance, the documented side-effect profile of Melanotan II, and what a licensed alternative looks like.

GHK-Cu + BPC-157 — claim review

Skin + tissue 'regeneration' combination. Topical GHK-Cu has cosmetic evidence; injectable use and BPC-157 do not. The leap from skincare data to injectable stack is not evidence-based.

MOTS-c + NAD+ — claim review

The mitochondrial longevity story. Neither compound has Phase 3 longevity-outcome trials. NMN / NR vs IV NAD+ distinction, and why exercise still wins.

Retatrutide grey-market supply — claim review

Retatrutide is investigational; no licensed reference product exists anywhere. Grey-market identity cannot be verified. The lawful UK route is registered clinical-trial enrolment.

Epitalon + MOTS-c — claim review

The headline biohacker longevity stack. Telomerase activation + mitochondrial signalling — mechanistic story exceeds Phase 3 outcome evidence by a wide margin.

Semax + Selank — claim review

Russian-developed nootropic combination. Some Russian-jurisdiction clinical use; healthy-adult cognitive-enhancement claims unsupported by Western Phase 3 trials.

Tesamorelin metabolic stack — claim review

Tesamorelin licensed in the US for HIV-associated lipodystrophy. Off-label use in 'metabolic stacks' for cosmetic visceral fat loss outruns the licensed indication evidence.

AOD-9604 fat-loss claims — claim review

AOD-9604 failed Phase 3 obesity development but persists in clinic marketing on the GRAS food-ingredient status. The honest fat-loss evidence picture.

Thymosin Alpha-1 + LL-37 — claim review

The 'immune optimisation' combination marketed for long COVID and chronic infections. TA1 is licensed in 35+ countries for specific indications; LL-37 is essentially untested in humans.

Peptide longevity stack claims — review

The whole-category review: Epitalon, MOTS-c, Humanin, GHK-Cu, NAD+ precursors. What they have in common — heavy marketing, mechanistic story, near-zero longevity-outcome trial evidence.

Peptide recovery stack claims — review

The whole-category review: BPC-157, TB-500, injectable GHK-Cu, GH secretagogues. Why physiotherapy remains the NHS evidence-based pathway.

Peptide fat-loss stack claims — review

The whole-category review: licensed GLP-1s combined with unlicensed AOD-9604 / tesamorelin / HGH Fragment. Why combining licensed and unlicensed peptides creates new risk without published benefit.

Peptide nootropic stack claims — review

The whole-category review: Semax, Selank, DSIP, Dihexa, Cerebrolysin. Russian-jurisdiction clinical use vs Western nootropic marketing.